Headlines

European pre-market summary - 27th October 2026: Futures falter as energy lifts and heavyweights dissapoint

Newsquawk Staff ·

Q3 Earnings

  • HSBC (HSBA LN), -5.3% in HK trade: PBT & Revenue missed. NII higher Y/Y. Affirms guidance, USD 1bln buyback.
  • Orange (ORA FP), +1.4%: Revenue beat, EBITDAaL higher Y/Y. EBITDAaL guidance upgraded.
  • Novartis (NOVN SW), +0.9%: Net in-line, adj. Operating Income and EPS beat. Upgrades FY26 Operating Income guide.
  • Alfa Laval (ALFA SS): Sales & Net miss, adj. EBITA & Orders beat.
  • Assa Abloy (ASSAN SS): Sales, EBITA and EBIT beat.

9M Earnings

  • Porsche AG (P911 GY), +2%: Revenue lower Y/Y, Operating Profit much higher Y/Y. Reaffirms guidance, above exp.

Pharmaceutical

  • Bayer (BAYN GY): Post hoc sub-analysis of key secondary endpoint data from the OASIS-1 and OASIS-2 pivotal trials for Lynkuet, in which the efficacy of Lynkuet for the treatment of moderate to severe hot flashes due to menopause was demonstrated.

Other

  • Engie (ENGI FP): Belgium is, according to De Tijd, considering compulsory nationalisation of nuclear assets as Engie negotiations struggle to make progress.
  • BE Semi (BESI NA): Applied Materials (AMAT) plans to raise its stake in the Co. to about 20% from 9%.
  • Universal Music Group (UMG NA): Reportedly discussed going private with buyout firms, Bloomberg reports.
  • Novo Nordisk (NOVOB DC): US judge rejects request to temporarily block Eli Lilly (LLY) from advertising claims that its drugs are more effective.

Related headlines